Patritumab is a monoclonal antibody that targets the human epidermal growth factor receptor 3 (HER3), which plays a significant role in cell signaling pathways related to cell growth and survival. This therapeutic agent is primarily investigated for its potential in treating various cancers, particularly those that exhibit overexpression of HER3. Patritumab functions by binding to the extracellular domain of HER3, inhibiting its activation and subsequent downstream signaling, which can lead to reduced tumor growth and proliferation. The substance is characterized by its specificity for HER3, making it a targeted therapy option. It is typically administered via injection and is part of ongoing clinical research to evaluate its efficacy and safety in combination with other treatments. As a biologic, patritumab is produced through recombinant DNA technology, and its development reflects the growing trend towards personalized medicine in oncology. Its unique mechanism of action distinguishes it from other HER family-targeting therapies, highlighting its potential role in enhancing treatment outcomes for patients with HER3-positive tumors.

Patritumab

1262787-83-6: Patritumab is a monoclonal antibody that targets the human epidermal growth factor receptor 3 (HER3), which plays a significant role in cell signaling pathways related to cell growth and survival. This therapeutic agent is primarily investigated for its potential in treating various cancers, particularly those that exhibit overexpression of HER3. Patritumab functions by binding to the extracellular domain of HER3, inhibiting its activation and subsequent downstream signaling, which can lead to reduced tumor growth and proliferation. The substance is characterized by its specificity for HER3, making it a targeted therapy option. It is typically administered via injection and is part of ongoing clinical research to evaluate its efficacy and safety in combination with other treatments. As a biologic, patritumab is produced through recombinant DNA technology, and its development reflects the growing trend towards personalized medicine in oncology. Its unique mechanism of action distinguishes it from other HER family-targeting therapies, highlighting its potential role in enhancing treatment outcomes for patients with HER3-positive tumors.

<p>Patritumab (U3-1287), an anti-HER3 antibody, may inhibit tumor growth and cancer cell division in non-small cell lung cancer.</p>

<p>Anti-Human HER3 Monoclonal Antibody</p>

CAS 1262787-83-6

Patritumab

Patritumab

Ref: TM-T76796

Patritumab

Ref: 3D-CLA1295